secwatch.observer — SEC 8-K summary
======================================

Issuer:     INVO Fertility, Inc. (IVF)
CIK:        0001417926
Form:       8-K
Filed at:   2024-09-20T23:59:59+00:00
Accession:  0001493152-24-037589
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01, 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INVO Bioscience receives Nasdaq bid-price deficiency notice; restates lease accounting for 2021–2024 periods
--------------------------------------------------------------------------------

- Nasdaq notified INVO on Sep 18, 2024, that bid price was below $1 for 34 consecutive days; 180-day cure to May 17, 2025.
- If not compliant by May 17, 2025, a second 180-day period may be granted if other initial listing standards are met.
- Company considering reverse stock split among options to regain compliance.
- Audit committee concluded financial statements from Jun 2021–Jun 2024 should no longer be relied upon due to incorrect discount rate used for operating lease ROU assets/liabilities.
- Restatement does not affect revenue, results, EPS, or net equity; no change to operations or compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1417926/000149315224037589/0001493152-24-037589-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1417926/000149315224037589/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-037589

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer